Flunarizine versus propranolol for preventing migraines in children
Official title: Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine Using the PedMIDAS Measuring Tool.
Run by RESnTEC, Institute of Research · NCT07354126 · Data updated 2026-11-12
This trial will test whether flunarizine or propranolol better reduces migraine attacks in children aged 8 to 15.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 8 Years to 15 Years |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | RESnTEC, Institute of Research Academic / other |
| Locations | 1 site (Lahore, Punjab Province) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | February 28, 2026 |
| Study ends | February 28, 2026 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07354126 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 8–15 with migraine (with or without aura) per ICHD-3, who have at least four migraine attacks per month and a PedMIDAS score of 11 or higher, and who have no contraindications to the study drugs.
✕Probably not a fit
Children with secondary headache disorders, known hypersensitivity or contraindications to flunarizine or propranolol (including certain heart or lung conditions), those unable to attend regular follow-ups, or recent participants in other trials are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional comparison gives children with migraine either flunarizine or propranolol as a preventive medication and follows them for changes in attack frequency and disability. Eligible participants are 8–15 years old, meet ICHD-3 migraine criteria, experience ≥4 attacks per month, and have a PedMIDAS score ≥11. Outcomes will include change in PedMIDAS score, migraine frequency, and recording of adverse events while participants attend regular in-person follow-ups at the study site. Safety exclusions include secondary headache causes and contraindications such as cardiovascular or respiratory conditions.
Why it matters
Potential benefit: If successful, the results could help clinicians choose the more effective and better-tolerated preventive medicine for children with frequent migraines, reducing attack frequency and disability.
How similar studies have gone: Both flunarizine and propranolol have shown preventive benefit in adult trials and in some pediatric reports, but direct head-to-head evidence in children is limited and results have been inconsistent.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children of any gender * Aged 8-15 years * Diagnosed with migraine (with/without aura) per International Classification of Headache Disorders, 3rd Edition (ICHD-3) criteria * A history of ≥4 migraine attacks/month for the preceding 3 months * With a PedMIDAS score ≥11 (moderate-to-severe impact) Exclusion Criteria: * Children with secondary headache disorders (e.g., due to infections, trauma, structural brain lesions) * Known hypersensitivity or contraindications to flunarizine or propranolol * Presence of cardiovascular disorders (e.g., bradycardia, heart block, hypotension, asthma) * Non-compliance or inability to attend regular follow-ups * Participation in another clinical trial within the last 3 months
Where it's running
-
The Children's Hospital Lahore
Lahore, Punjab Province, Pakistan Recruiting
Study contacts
- Principal investigator: Ishafaq Ahmed, FCPS — The Children's Hospital Lahore
- Study coordinator: Ishafaq Ahmed, FCPS
- Email: quaidian245ishfaq@gmail.com
- Phone: +923334957171
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote electrical neuromodulation to test pain inhibition in migraine and fibromyalgia
We’re testing if the Nerivio wearable can boost the body’s natural pain-inhibition system (CPM) and reduce pain more than a sham device in adults with migraine or fibromyalgia.
-
Elismetrep (K-304) for acute treatment of migraine
This study tests whether a single dose of elismetrep can quickly lessen the pain of a migraine compared with placebo in adults 18 to 75.
-
Magnesium sulfate for acute non-traumatic headache in the ED: 2 g vs 4 g vs standard paracetamol
This study tests whether intravenous magnesium sulfate given in different doses helps adults with acute non-traumatic headache in the emergency department, compared with paracetamol.
-
HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry
This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.
-
OCT in Neurological Practice: Use of Retinal Layers to Help Diagnose and Follow Neurological Diseases
This study tests whether optical coherence tomography (OCT) of the retina can help in diagnosing and tracking multiple sclerosis, Alzheimer's, Parkinson's, migraines, and other headaches compared with healthy people.
-
Online Hatha Yoga Add-On for High-Frequency Episodic Migraine
This trial tests whether a 12-week online Hatha yoga program added to usual migraine treatment can help adults with high-frequency episodic migraine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.